Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response
Abstract Background Ethiopia rolled out primaquine nationwide in 2018 for radical cure along with chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in its bid for malaria elimination by 2030. The emergence of anti-malarial drug resistance would challenge the elimination goal. T...
Published in: | Malaria Journal |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMC
2023
|
Subjects: | |
Online Access: | https://doi.org/10.1186/s12936-023-04562-x https://doaj.org/article/17bcfce7722a43f991a38af86afa7003 |
id |
ftdoajarticles:oai:doaj.org/article:17bcfce7722a43f991a38af86afa7003 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:17bcfce7722a43f991a38af86afa7003 2023-06-11T04:10:01+02:00 Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response Daniel Abebe Mekonnen Girma Shumie Abadura Sinknesh Wolde Behaksra Hiwot Solomon Taffese Gudissa Aseffa Bayissa Mikiyas Gebremichael Bulto Tesfaye Sisay Tessema Fitsum G. Tadesse Endalamaw Gadisa 2023-04-01T00:00:00Z https://doi.org/10.1186/s12936-023-04562-x https://doaj.org/article/17bcfce7722a43f991a38af86afa7003 EN eng BMC https://doi.org/10.1186/s12936-023-04562-x https://doaj.org/toc/1475-2875 doi:10.1186/s12936-023-04562-x 1475-2875 https://doaj.org/article/17bcfce7722a43f991a38af86afa7003 Malaria Journal, Vol 22, Iss 1, Pp 1-11 (2023) Chloroquine Ethiopia P. vivax Primaquine Treatment failure Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2023 ftdoajarticles https://doi.org/10.1186/s12936-023-04562-x 2023-05-07T00:36:06Z Abstract Background Ethiopia rolled out primaquine nationwide in 2018 for radical cure along with chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in its bid for malaria elimination by 2030. The emergence of anti-malarial drug resistance would challenge the elimination goal. There is limited evidence on the emergence of chloroquine drug resistance. The clinical and parasitological outcomes of treatment of P. vivax with chloroquine plus radical cure using low dose 14 days primaquine were assessed in an endemic area of Ethiopia. Methods A semi-directly observed 42-days follow up in-vivo therapeutic efficacy study was conducted from October 2019 to February 2020. Plasmodium vivax mono-species infected patients (n = 102) treated with a 14 days low dose (0.25 mg/kg body weight per day) primaquine plus chloroquine (a total dose of 25 mg base/kg for 3 days) were followed for 42 days to examine clinical and parasitological outcomes. Samples collected at recruitment and days of recurrence were examined by 18 S based nested polymerase chain reaction (nPCR) and Pvmsp3α nPCR-restriction fragment length polymorphism. Asexual parasitaemia and the presence of gametocytes were assessed on the scheduled days using microscopy. Clinical symptoms, haemoglobin levels, and Hillmen urine test were also assessed. Results Of the 102 patients followed in this study, no early clinical and parasitological failure was observed. All patients had adequate clinical and parasitological responses within the 28 days of follow up. Late clinical (n = 3) and parasitological (n = 6) failures were observed only after day 28. The cumulative incidence of failure was 10.9% (95% confidence interval, 5.8–19.9%) on day 42. Among the paired recurrent samples, identical clones were detected only in two samples on day 0 and day of recurrences (day 30 and 42) using Pvmsp3α genotyping. No adverse effect was detected related to the low dose 14 days primaquine administrations. Conclusion Co-administration of CQ with PQ in the study area is ... Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arba ENVELOPE(144.373,144.373,59.682,59.682) Arctic Malaria Journal 22 1 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Chloroquine Ethiopia P. vivax Primaquine Treatment failure Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
spellingShingle |
Chloroquine Ethiopia P. vivax Primaquine Treatment failure Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 Daniel Abebe Mekonnen Girma Shumie Abadura Sinknesh Wolde Behaksra Hiwot Solomon Taffese Gudissa Aseffa Bayissa Mikiyas Gebremichael Bulto Tesfaye Sisay Tessema Fitsum G. Tadesse Endalamaw Gadisa Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response |
topic_facet |
Chloroquine Ethiopia P. vivax Primaquine Treatment failure Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
description |
Abstract Background Ethiopia rolled out primaquine nationwide in 2018 for radical cure along with chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in its bid for malaria elimination by 2030. The emergence of anti-malarial drug resistance would challenge the elimination goal. There is limited evidence on the emergence of chloroquine drug resistance. The clinical and parasitological outcomes of treatment of P. vivax with chloroquine plus radical cure using low dose 14 days primaquine were assessed in an endemic area of Ethiopia. Methods A semi-directly observed 42-days follow up in-vivo therapeutic efficacy study was conducted from October 2019 to February 2020. Plasmodium vivax mono-species infected patients (n = 102) treated with a 14 days low dose (0.25 mg/kg body weight per day) primaquine plus chloroquine (a total dose of 25 mg base/kg for 3 days) were followed for 42 days to examine clinical and parasitological outcomes. Samples collected at recruitment and days of recurrence were examined by 18 S based nested polymerase chain reaction (nPCR) and Pvmsp3α nPCR-restriction fragment length polymorphism. Asexual parasitaemia and the presence of gametocytes were assessed on the scheduled days using microscopy. Clinical symptoms, haemoglobin levels, and Hillmen urine test were also assessed. Results Of the 102 patients followed in this study, no early clinical and parasitological failure was observed. All patients had adequate clinical and parasitological responses within the 28 days of follow up. Late clinical (n = 3) and parasitological (n = 6) failures were observed only after day 28. The cumulative incidence of failure was 10.9% (95% confidence interval, 5.8–19.9%) on day 42. Among the paired recurrent samples, identical clones were detected only in two samples on day 0 and day of recurrences (day 30 and 42) using Pvmsp3α genotyping. No adverse effect was detected related to the low dose 14 days primaquine administrations. Conclusion Co-administration of CQ with PQ in the study area is ... |
format |
Article in Journal/Newspaper |
author |
Daniel Abebe Mekonnen Girma Shumie Abadura Sinknesh Wolde Behaksra Hiwot Solomon Taffese Gudissa Aseffa Bayissa Mikiyas Gebremichael Bulto Tesfaye Sisay Tessema Fitsum G. Tadesse Endalamaw Gadisa |
author_facet |
Daniel Abebe Mekonnen Girma Shumie Abadura Sinknesh Wolde Behaksra Hiwot Solomon Taffese Gudissa Aseffa Bayissa Mikiyas Gebremichael Bulto Tesfaye Sisay Tessema Fitsum G. Tadesse Endalamaw Gadisa |
author_sort |
Daniel Abebe Mekonnen |
title |
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response |
title_short |
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response |
title_full |
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response |
title_fullStr |
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response |
title_full_unstemmed |
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response |
title_sort |
treatment of uncomplicated plasmodium vivax with chloroquine plus radical cure with primaquine without g6pdd testing is safe in arba minch, ethiopia: assessment of clinical and parasitological response |
publisher |
BMC |
publishDate |
2023 |
url |
https://doi.org/10.1186/s12936-023-04562-x https://doaj.org/article/17bcfce7722a43f991a38af86afa7003 |
long_lat |
ENVELOPE(144.373,144.373,59.682,59.682) |
geographic |
Arba Arctic |
geographic_facet |
Arba Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Malaria Journal, Vol 22, Iss 1, Pp 1-11 (2023) |
op_relation |
https://doi.org/10.1186/s12936-023-04562-x https://doaj.org/toc/1475-2875 doi:10.1186/s12936-023-04562-x 1475-2875 https://doaj.org/article/17bcfce7722a43f991a38af86afa7003 |
op_doi |
https://doi.org/10.1186/s12936-023-04562-x |
container_title |
Malaria Journal |
container_volume |
22 |
container_issue |
1 |
_version_ |
1768384082714034176 |